Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Abbott Laboratories : Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/20/2012 | 03:05pm CET

ABBOTT PARK, Ill., April 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration clearance to use its iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS Laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide.

Nearly 3 million patients undergo cataract surgery each year in the United States. With this new clearance, the iFS Laser now gives surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

Factors such as placement, length, depth and radius of curvature can influence the surgeon's desired change to the cornea. These parameters can be difficult to control through traditional incisions made by hand using surgical knives. Now, using the iFS Laser, arcuate incisions can be performed with greater precision, predictability and customization than is possible with a manual technique.

"This is a major advancement and expansion of our Femtosecond laser technology," said Jim Mazzo, senior vice president, Abbott Medical Optics. "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize Femtosecond laser technology as a potential standard of care during the cataract procedure."

Study data support that the iFS Femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards.

This new use of Abbott's iFS Femtosecond laser is available now in the United States.

About Abbott Medical Optics (AMO)

Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. Products in the cataract line include monofocal and multifocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards. Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears.

For more information, please visit www.abbottmedicaloptics.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
08:44p MYLAN : EpiPen maker Mylan to restructure, cut workforce
07:47pDJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
07:15pDJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
07:00p ABBOTT LABORATORIES : Alere Issues Statement Regarding Abbott Lawsuit
05:53p ALERE : Abbott seeks to end buyout deal for Alere
05:15p ABBOTT : Seeks to Terminate Alere Acquisition
12/06 STUDY : Hospital Nutrition Program Shortens Patient Stays and Reduces Readmissio..
12/01 ABBOTT LABORATORIES : Trademark Application for "ABBOTT REALTIME" Filed by Abbot..
12/01 ABBOTT LABORATORIES : An Application for the Trademark "STRONGBABIES SYSTEM" Has..
11/30 ABBOTT : Announces CE Mark for i-STAT Alinity, a Pioneering, Handheld Blood Test..
More news
Sector news : Pharmaceuticals - NEC
08:44p MYLAN : EpiPen maker Mylan to restructure, cut workforce
07:16pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
05:34pDJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
04:19pDJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
02:21pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:11p Alere takes issue with Abbott on its plan to walk away
03:03p Alere Presents A Potential Holiday Sale Opportunity For Merger Arbitrage Inve..
01:26p Is Rebalancing A Stock Portfolio A Form Of Value Investing?
11:43a Abbott to back out of Alere deal
12/05 DECEMBER WATCH LIST : Nike, Disney And Abbott All Could Offer At Least 14% Poten..